Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience.

Autor: Elboga U; Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey., Sahin E; Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey., Cayirli YB; Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey., Okuyan M; Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey., Aktas G; Department of Oncology, Medical Park Private Hospital, Gaziantep 27090, Turkey., Haydaroglu Sahin H; Department of Hematology, Gaziantep University, Gaziantep 27310, Turkey., Dogan I; Department of Biostatistics, Gaziantep University, Gaziantep 27310, Turkey., Kus T; Department of Oncology, Gaziantep University, Gaziantep 27310, Turkey., Akkurd DM; Department of Hematology, Gaziantep University, Gaziantep 27310, Turkey., Cimen U; Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey., Mumcu V; Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey., Kilbas B; Department of R&D, Moltek Health Services Production & Marketing Inc., Kocaeli 41400, Turkey., Celen YZ; Department of Nuclear Medicine, Gaziantep University, Gaziantep 27310, Turkey.
Jazyk: angličtina
Zdroj: Tomography (Ann Arbor, Mich.) [Tomography] 2022 Feb 01; Vol. 8 (1), pp. 293-302. Date of Electronic Publication: 2022 Feb 01.
DOI: 10.3390/tomography8010024
Abstrakt: Objective: In this study, we aimed to compare [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging to detect lesions in multiple myeloma.
Methods: A total of 14 patients with multiple myeloma who underwent [68Ga]FAPI PET/CT and [18F]FDG PET/CT imaging were included in this retrospective study. SUV max values of [68Ga]FAPI and [18F]FDG were compared according to lesion locations. Also, lesion localization ability of both imaging methods was compared on the patient basis.
Results: In 4 of 14 patients, [68Ga]FAPI PET/CT and [18F]FDG PET/CT have not detected any bone lesions. In 8 of the remaining 10 patients [18F]FDG PET/CT detected bone lesions but in this group, 6 patients showed more higher SUV max values than [18F]FDG PET/CT in [68Ga]FAPI PET/CT.In contrast, 2 of 8 patients showed more higher SUV max values than [68Ga]FAPI PET/CT in [18F]FDG PET/CT. Moreover, [68Ga]FAPI PET/CT detected bone lesions in two patients, which werenot detected by [18F]FDG PET/CT. Also, in five patients, [68Ga]FAPI PET/CT showed more bone lesions in comparison with[18F]FDG PET/CT. Only one patient, [18F]FDG PET/CT showed more bone lesions. Three extramedullary involvements were observed in the following locations: lung, presacral lymph node, and soft tissue mass lateral to the right maxillary sinus. Among these involvements, higher SUV max values were observed in the lung and presacral lymph node with [68Ga]FAPI compared to [18F]FDG. However, the soft tissue mass showed a higher SUV max value in [18F]FDG than [68Ga]FAPI.
Conclusions: No significant superiority was observed in [68Ga]FAPI PET/CT over [18F]FDG PET/CT in patients with MM. However, [68Ga]FAPI PET/CT can be utilized as a complementary imaging method to [18F]FDG PET/CT in some settings, especially in low-[18F]FDG affinity and inconclusive cases. Considering the favorable aspects of [68Ga]FAPI PET/CT in MM, such as low background activity, absence of non-specific bone marrow, and physiological brain involvement, further studies with a larger sample size should be conducted.
Databáze: MEDLINE
Externí odkaz: